Talopram

DB09190

small molecule experimental

Deskripsi

Talopram is a selective norepinephrine reuptake inhibitor (SNRI) that is structurally similar to citalopram and melitracen. It was researched in the 1960s and 1970s but never marketed.

Struktur Molekul 2D

Berat 295.426
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

677 Data
Buprenorphine Talopram may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Hydrocodone Talopram may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Magnesium sulfate The therapeutic efficacy of Talopram can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Talopram may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Talopram may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Mirtazapine Talopram may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Orphenadrine Talopram may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Talopram may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Pramipexole Talopram may increase the sedative activities of Pramipexole.
Ropinirole Talopram may increase the sedative activities of Ropinirole.
Rotigotine Talopram may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Talopram.
Sodium oxybate Talopram may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Talopram may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Thalidomide Talopram may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Talopram may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Talopram.
Dicoumarol The risk or severity of adverse effects can be increased when Talopram is combined with Dicoumarol.
Phenindione The risk or severity of adverse effects can be increased when Talopram is combined with Phenindione.
Warfarin The risk or severity of adverse effects can be increased when Talopram is combined with Warfarin.
Phenprocoumon The risk or severity of adverse effects can be increased when Talopram is combined with Phenprocoumon.
Acenocoumarol The risk or severity of adverse effects can be increased when Talopram is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of adverse effects can be increased when Talopram is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of adverse effects can be increased when Talopram is combined with Coumarin.
(R)-warfarin The risk or severity of adverse effects can be increased when Talopram is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of adverse effects can be increased when Talopram is combined with Ethyl biscoumacetate.
Fluindione The risk or severity of adverse effects can be increased when Talopram is combined with Fluindione.
Clorindione The risk or severity of adverse effects can be increased when Talopram is combined with Clorindione.
Diphenadione The risk or severity of adverse effects can be increased when Talopram is combined with Diphenadione.
Tioclomarol The risk or severity of adverse effects can be increased when Talopram is combined with Tioclomarol.
(S)-Warfarin The risk or severity of adverse effects can be increased when Talopram is combined with (S)-Warfarin.
Ethanol Talopram may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Talopram may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Fluvoxamine The risk or severity of adverse effects can be increased when Talopram is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Talopram is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Talopram is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Talopram is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Talopram is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Talopram is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Talopram is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Talopram is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Talopram is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Talopram is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Talopram is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Talopram is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Talopram is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Talopram is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Talopram is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Talopram is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Talopram is combined with Alaproclate.
Iobenguane Talopram can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.
Zopiclone The risk or severity of adverse effects can be increased when Talopram is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Talopram.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Talopram.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Talopram.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Talopram.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Talopram.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Talopram.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Talopram.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Talopram.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Talopram.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Talopram.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Talopram.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Talopram.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Talopram.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Talopram.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Talopram.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Talopram.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Talopram.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Talopram.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Talopram.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Talopram.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Talopram.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Talopram.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Talopram.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Talopram.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Talopram.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Talopram.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Talopram.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Talopram.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Talopram.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Talopram.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Talopram.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Talopram.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Talopram.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Talopram.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Talopram.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Talopram.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Talopram.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Talopram.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Talopram.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul